Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
暂无分享,去创建一个
M. Rooney | B. Poiesz | S. Graziano | N. Newman | L. Kohman | G. Gamble | L. Abbott | S. Mookherjee | M. Lamb | Stephen L. Graziano | Bernard J. Poiesz | Nancy Newman | Gary P. Gamble | Lynn Abbott | Michelle Rooney | Sulagna Mookherjee | Melissa L. Lamb
[1] S. Rodenhuis,et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.
[2] P. Zimmerman,et al. PLOIDY AS A PROGNOSTIC DETERMINANT IN SURGICALLY TREATED LUNG CANCER , 1987, The Lancet.
[3] Johnson Be,et al. The biology of lung cancer. , 1993, Seminars in oncology.
[4] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[5] S. Rodenhuis,et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. , 1994, The Journal of clinical investigation.
[6] S. Rodenhuis,et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.
[7] J. Mate,et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.
[8] M. Gail,et al. Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group , 1984, Cancer.
[9] D. Weiner,et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.
[10] C. Mountain,et al. Revisions in the International System for Staging Lung Cancer. , 1997, Chest.
[11] S. Steinberg,et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.
[12] A. Ariza,et al. Molecular staging of non-small cell lung cancer according to K-ras genotypes. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] A. Sahin,et al. Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. , 1991, The New England journal of medicine.
[14] J. Roh,et al. Correlation between K‐ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma , 1997, Cancer.
[15] S. Finkelstein,et al. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. , 1993, Archives of surgery.
[16] A. Tong,et al. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. , 1998, American journal of clinical oncology.
[17] K. Sugimachi,et al. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.
[18] J. Siegfried,et al. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] K. Suemasu,et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 CM in diameter , 1988, Cancer.
[20] H. Dosaka-akita,et al. Prognostic significance of the expression of ras oncogene product in non‐small cell lung cancer , 1992, Cancer.
[21] M. Wigler,et al. Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1 , 1983, Nature.
[22] Y. Fujiwara,et al. Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection , 1994, Japanese journal of cancer research : Gann.
[23] W. Richards,et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Zimmerman,et al. Ploidy of Surgically Treated Primary Lung-Cancer , 1987 .
[25] J. Siegfried,et al. Prognostic value of specific KRAS mutations in lung adenocarcinomas. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[26] M. Sherman,et al. HTLV‐I DNA Sequences in CNS Tissue of a Patient with Tropical Spastic Paraparesis and HTLV‐I‐Associated Myelopathy , 1992, Journal of acquired immune deficiency syndromes.
[27] C. Angeletti,et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.
[28] David J. Sharkey,et al. Antibodies as Thermolabile Switches: High Temperature Triggering for the Polymerase Chain Reaction , 1994, Bio/Technology.
[29] T Takahashi,et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.
[30] S. Rodenhuis,et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.
[31] K. Inoue,et al. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non‐small cell lung cancer , 1990, Cancer.
[32] J. Minna,et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. , 1991, Oncogene.
[33] M. Barbacid,et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. , 1984, Science.